enGene Holdings Inc. (ENGN)

Market Cap	661.51M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	44.10M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,804
Open	14.92
Previous Close	14.72
Day's Range	14.00 - 15.22
52-Week Range	6.69 - 47.17
Beta	-0.49
Analysts	Strong Buy
Price Target	34.40 (+129.33%)
Earnings Date	Mar 11, 2024

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN

Analyst Forecast

According to 5 analysts, the average rating for ENGN stock is "Strong Buy." The 12-month stock price forecast is $34.4, which is an increase of 129.33% from the latest price.

Price Target

$34.4

(129.33% upside)

Analyst Consensus: Strong Buy